News from ABPI, Cubist and Oxford Pharmascience – People on the move

By Natalie Morrison

- Last updated on GMT

Related tags Pharmacology

News from ABPI, Cubist and Oxford Pharmascience – People on the move
in-PharmaTechnologist.com presents its weekly round-up of the latest chops and changes on the pharmaceutical careers ladder, including news from ABPI, Cubist and Oxford Pharmascience.

The ABPI​ (Association of the British Pharmaceutical Industry) has hired Bina Rawal​ as its new Medical, Innovation and Research Director.

She joins the organisation from the Wellcome Trust​ where she was head of clinical development within the technology transfer division.

In her new role, she will take focus on the productivity of the innovation process in the UK and will be the senior medical spokesperson for the ABPI to the Government, the media and other professional bodies.

Cubist Pharmaceuticals​ has named Robert Perez​ as its new president and COO.

Formerly executive VP and COO, Perez will all global commercial, manufacturing, business development, and information technology.

VP of corporate finance Michael Tomsicek​ has also been handed a promotion and will now become senior VP and deputy CFO.

Oxford Pharmascience​ has drafted James White​ onto its board as deputy to chairman David Norwood.

He will work on the firm’s business development and corporate relations programme, which seeks to make more deals along the lines of a recent one with Bayer over Oxford’s soft chew technology. 
Marc Kozin​ has joined the Endocyte​ board of directors.

Currently a senior advisor to global strategy provider L.E.K. Consulting, he joins the firm as it launches its new growth strategy.

Ron Ellis, president and CEO of Endocyte, said: "His leadership in biopharmaceutical consulting brings a tremendous breadth of experience and strong industry relationships to support many of the decisions Endocyte will face as we grow."

Collegium Pharmaceutical​ has appointed Gino Santini​ to its board.

Santini joins the firm after retiring from his 27-year career with Eli Lilly, where he was most recently senior VP of corporate strategy and business development.

“As we progress our lead candidate, an extended-release, tamper-resistant oxycodone product for the treatment of chronic pain (COL-003), toward NDA filing, Gino’s expertise in commercialisation and business development will be instrumental in assisting the company in choosing our strategic path,”​ said Michael Heffernan, CEO.

Caisson Biotech​ has employed Glenn Nedwin ​as CEO and president. 

Previously, he was executive VP of Genencor Division of Danisco, recently acquired by DuPont.

He will now drive the expansion of the firm’s HEPtune drug delivery enhancement technology.

“We are seeking additional corporate partners for our technology and we intend to become a leader in drug delivery,”​ said Nedwin.

Related topics Markets & Regulations

Related news

Show more

Follow us

Products

View more

Webinars